Recent

% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

  • hbomb57108 hbomb57108 Feb 12, 2013 11:03 PM Flag

    Dasatanib phase 3 prostate failure

    No OS difference between DAS/D and PBO/D (median, 21.5 vs. 21.2 mos; hazard ratio [HR], 0.99; log-rank P = 0.90) was observed. Results of secondary endpoints for DAS/D vs. PBO/D were: ORR (30.5 vs. 31.9%); TFSRE (median, not reached vs. 31.1 mos; HR, 0.81 [95% CI, 0.64-1.02]); uNTX reduction (66.0 vs. 60.6%); PFS (median, 11.8 vs. 11.1 mos; HR, 0.92); TPSAP (median, 8.0 vs. 7.6 mos; HR, 0.91), and pain reduction (66.6 vs. 71.5%). Twenty-three percent of DAS/D and 14% of PBO/D pts received therapy for

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • wow! no huge surprise I guess since it was originally intended to be a "new and improved" Gleevec. But still, just goes to show one kinase inhibitor does not fit all.

      thanks hbomb. what a name. where the hell did you come up with that? you work in the nuke industry? my graduate degree is in cellular/molecular radiation bio - loads of nuclear phiz.

      Joe

      • 1 Reply to joeflow77
      • "where the hell did you come up with that?

        I created this account when I was in my late teens/early 20's. I originally started account to play card games like spades.(card games have a calming affect on me) First letter of last name, term to describe my wild reckless behaviors at the time, zip code.

        "you work in the nuke industry? my graduate degree is in cellular/molecular radiation bio - loads of nuclear phiz."

        Yes, I graduated with Associate's in height of the nuclear cardiology boom.

 
EXEL
8.76+0.12(+1.39%)Jul 27 4:00 PMEDT